92584-63-9

Usage

Uses

Used in Organic Synthesis:
1-Propanol, 3-(3-bromophenoxy)is used as a starting material for the production of other chemicals. Its unique structure allows for further reactions and modifications, making it a valuable component in the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
1-Propanol, 3-(3-bromophenoxy)is used as a chemical intermediate in the development of pharmaceuticals. The bromophenoxy group may contribute to the biological activity of the resulting compounds, and further research may uncover more potential uses for this chemical in drug development.
Used in Chemical Intermediates Production:
1-Propanol, 3-(3-bromophenoxy)is used as a chemical intermediate for the production of other compounds. Its versatility in organic synthesis makes it a valuable precursor for the creation of a wide range of chemical products.

Upstream product

• 591-20-8 3-Bromophenol 
• 627-18-9 1-bromo-3-propanol 

Downstream Products

• 156450-01-0 1-bromo-3-(3-bromopropoxy)benzene 
• 127973-09-5 3-(3-bromophenoxy)propanal 
• 1429323-82-9 C₁₇H₁₉N₅O₃ 
• 1429323-81-8 C₃₄H₄₇N₅O₉ 
• 1429323-80-7 C₁₇H₂₅BO₅ 
• 129789-91-9 3-(3-bromo-phenoxy)-propionic acid ethyl ester 
• 18386-03-3 3-(3-bromophenoxy)propionic acid 

Relevant academic research and scientific papers

Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP3 prostanoid receptor

Potent and selective ligands for the human EP3 prostanoid receptor are described. Biaryl compounds bearing a tethered ortho substituted acidic moiety were identified as potent EP3 antagonists based on the SAR described herein. The binding affinity of key compounds on all eight human prostanoid receptors is reported.

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

MACROCYCLIC LRRK2 KINASE INHIBITORS

The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease